Propanc Biopharma, Inc. (PPCB)
- Previous Close
0.0010 - Open
0.0010 - Bid --
- Ask --
- Day's Range
0.0009 - 0.0010 - 52 Week Range
0.0001 - 0.2625 - Volume
5,451,113 - Avg. Volume
5,233,383 - Market Cap (intraday)
44,323 - Beta (5Y Monthly) 1.82
- PE Ratio (TTM)
0.00 - EPS (TTM)
0.2400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
www.propanc.comRecent News: PPCB
Performance Overview: PPCB
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PPCB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PPCB
Valuation Measures
Market Cap
44.32k
Enterprise Value
990.58k
Trailing P/E
0.00
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-518.35%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-2.73M
Diluted EPS (ttm)
0.2400
Balance Sheet and Cash Flow
Total Cash (mrq)
71.65k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-436.39k
Research Analysis: PPCB
Company Insights: PPCB
PPCB does not have Company Insights